Back to results
US 7,888,020 B2Granted
Association of EDG5 polymorphism V286A with type II diabetes mellitus and venous thrombosis/pulmonary embolism and the use thereof
AssigneeSanofi-Aventis Deutschland GmbH
InventorsDetlef Kozian, Evi Kostenis, Karl-Ernst Siegler, Martina Jacobs, Sylvain Ricard, Sandrine Mace, Jean-Francois Deleuze
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method of identifying an increase in risk for type II Diabetes mellitus, venous thrombosis, or pulmonary embolism in a subject, wherein the presence of an amino acid exchange at position 286 from valine (Val) to alanine (Ala) in the EDG5 protein in a biological sample taken from the subject.
Claims1
A method for identifying an increase risk for type II diabetes mellitus in a human subject, comprising the steps of:
- (a) removing a biological sample from the human subject that comprises a nucleic acid sequence that encodes EDG5 protein;
- (b) screening genomic DNA of said human subject for single polynucleotide polymorphism (SNP) by polymerase chain reaction amplification (PCR) of DNA encoding position 286 of SEQ ID NO:3 of EDGE5 Protein;
- and
- (c) detecting the presence of a nucleotide sequence that encodes for an alanine at position 286 of SEQ ID NO. 3 wherein the presence of the nucleotide sequence is correlated with an increased risk for type II diabetes mellitus in said human subject.
1 more element
Dependencies are inferred from the claim text.